Buvoli M, Buvoli A, Leinwand L A
Department of Molecular Biology, University of Colorado at Boulder, Boulder, Colorado 80309, USA.
Mol Cell Biol. 2000 May;20(9):3116-24. doi: 10.1128/MCB.20.9.3116-3124.2000.
We demonstrate here the first experimental suppression of a premature termination codon in vivo by using an ochre suppressor tRNA acting in an intact mouse. Multicopy tRNA expression plasmids were directly injected into skeletal muscle and into the hearts of transgenic mice carrying a reporter gene with an ochre mutation. A strategy for modulation of suppressor efficiency, applicable to diverse systems and based on tandem multimerization of the tRNA gene, is developed. The product of suppression (chloramphenicol acetyltransferase) accumulates linearly with increases in suppressor tRNA concentration to the point where the ochre-suppressing tRNA(Ser) is in four- to fivefold excess over the endogenous tRNA(Ser). The subsequent suppressor activity plateau seems to be attributable to accumulation of unmodified tRNAs. These results define many salient variables for suppression in vivo, for example, for tRNA suppression employed as gene therapy for nonsense defects.
我们在此展示了首次在体内通过使用在完整小鼠中起作用的赭石抑制tRNA对提前终止密码子进行实验性抑制。将多拷贝tRNA表达质粒直接注射到携带带有赭石突变的报告基因的转基因小鼠的骨骼肌和心脏中。开发了一种适用于多种系统且基于tRNA基因串联多聚化的调节抑制效率的策略。抑制产物(氯霉素乙酰转移酶)随着抑制性tRNA浓度的增加而线性积累,直至赭石抑制性tRNA(Ser)比内源性tRNA(Ser)多出四到五倍。随后抑制活性的平台期似乎归因于未修饰tRNA的积累。这些结果定义了体内抑制的许多显著变量,例如,用于对无义缺陷进行基因治疗的tRNA抑制。